LPPEPTIDE | Retatrutide 30mg | 30mg x 10 vials | 10 vials / box

What is RT30?

Triple-receptor incretin agonist profile for metabolic research. The LPPEPTIDE knowledge record describes Retatrutide as an investigational GLP-1, GIP, and glucagon receptor agonist studied in obesity and type 2 diabetes models, with phase II research reporting high-dose body-weight reduction up to 24% over 48 weeks. Retatrutide 30mg is mapped to LPPeptide SKU RT30. Current storefront values use our product data: 30mg x 10 vials /box, $199.00 USD per box. LPPeptide reference specs: 5mg x 10 vials / 10mg x 10 vials / 15mg x 10 vials / 20mg x 10 vials / 30mg x 10 vials / 40mg x 10 vials / 60mg x 10 vials.

Research context

The LPPEPTIDE knowledge record describes Retatrutide as an investigational GLP-1, GIP, and glucagon receptor agonist studied in obesity and type 2 diabetes models, with phase II research reporting high-dose body-weight reduction up to 24% over 48 weeks. Research typically centers on GLP-1, GIP, and glucagon receptor signaling, with endpoints such as appetite signaling, glucose handling, and energy balance models.

Commonly matched with

RT30 is commonly reviewed alongside RT10, RT20, TR10, TR20, Tirzepatide. Keep each combination tied to a defined research objective and lot record.

Compliance notice

RT30 is supplied for research use only. It is not for human or veterinary use, not for consumption, and statements on this page are reference context rather than medical claims.

Reference literature focus

The LPPEPTIDE knowledge record describes Retatrutide as an investigational GLP-1, GIP, and glucagon receptor agonist studied in obesity and type 2 diabetes models, with phase II research reporting high-dose body-weight reduction up to 24% over 48 weeks. Research typically centers on GLP-1, GIP, and glucagon receptor signaling, with endpoints such as appetite signaling, glucose handling, and energy balance models.

Study design notes

Use the LPPeptide product knowledge record, current LPPeptide COA, and internal lab SOP to confirm identity, concentration, and endpoints before this material enters a study. The matched LPPeptide reference specification is 5mg x 10 vials / 10mg x 10 vials / 15mg x 10 vials / 20mg x 10 vials / 30mg x 10 vials / 40mg x 10 vials / 60mg x 10 vials.

LPPeptide handling reference

1.Using a sterile syringe, withdraw 1.0 mL of bacteriostatic water.

2.Slowly inject the diluent along the inner wall of the vial; avoid foaming.

3.Gently swirl or roll the vial until completely dissolved. Do not shake.

4.Label the vial with the date of reconstitution and store refrigerated at 2–8°C, protected from light.

5.Use the reconstituted solution within 4 weeks.

Preparation

Reconstitution: Add 1.0 mL of bacteriostatic water to yield a concentration of approximately 5.0 mg/mL. Dosage Regimen: The typical dose range is 2–8 mg administered once weekly, with gradual titration over 8–12 weeks. Dose Conversion: At a concentration of 5.0 mg/mL, 1 unit (0.01 mL) on a U-100 insulin syringe is equivalent to approximately 50 mcg.

Storage

Lyophilized: -20 deg C or below, dry and dark. Reconstituted: 2-8 deg C, protect from light, use within about 4 weeks, and let the sealed vial reach room temperature before opening to reduce condensation.. Follow the most current lot-specific handling record whenever it is available.

Safety observations

Published discussion commonly focuses on gastrointestinal tolerance, hydration status, appetite-pathway effects, and limited long-term human safety data.

Contraindications

Do not use RT30 outside qualified research workflows. Review the current SDS, COA, and protocol exclusions before handling.

Interaction review

Use extra caution in models involving other incretin, glucose-lowering, appetite, or gastric-emptying pathways.

Certificate of Analysis

Each LPPeptide lot should be confirmed against current batch documentation before shipment or study use. This product page keeps RT30 visible so the SKU can be matched to the active COA.

Current catalog summary

• SKU: RT30
• Product: Retatrutide 30mg
• Storefront specification: 30mg x 10 vials /box
• LPPeptide reference specs: 5mg x 10 vials / 10mg x 10 vials / 15mg x 10 vials / 20mg x 10 vials / 30mg x 10 vials / 40mg x 10 vials / 60mg x 10 vials
• Listed box price: $199.00 USD
• Reference: LPPeptide product knowledge record

Testing checklist

• Peptide identity or material identity
• HPLC purity or assay result where applicable
• Batch ID and test date
• Sterility/endotoxin or accessory checks when applicable
• Residual solvent and handling notes where applicable

Direct catalog supply

LPPeptide product pages use our own SKU, package, price, and stock data first. LPPeptide knowledge mapping adds compound education, handling notes, and specification checks while lot-specific editorial content is being prepared.

Lot-specific content

For final release decisions, use the current product record, COA, handling sheet, and research SOP as the highest-priority source for this page.